BriaCell Therapeutics Corp. (BCTX), a clinical-stage immuno-oncology-focused biotechnology company, priced its public offering of 1.45 million shares at $3.25 per share.
The total gross proceeds from the offering are expected to be approximately $4.7 million, and the offering is expected to close on June 2, 2026, subject to closing conditions.
The company intends to use the net proceeds from the offering for working capital requirements, general corporate purposes, and advancing its business objectives.
ThinkEquity is acting as the sole placement agent for the offering.
BCTX has traded between $2.98 and $36.90 over the last year. The stock closed Friday's trade at $3.64, up 1.68%.
In the overnight market, BCTX is down 12.64% at $3.18.
For More Such Biotech Stock News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.